Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO

Written By Carla Aguilera

Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN

MAbs. 2018 Jan;10(1):55-61. doi: 10.1080/19420862.2017.1402997. Epub 2017 Dec 5. PMID: 29120699; PMCID: PMC5800385.

Carla Aguilera
Previous

Topotecan-Vincristine-Doxorubicin in Stage 4 HR NBL Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Next

Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes